home / stock / axsm / axsm articles

AXSM Articles, Axsome Therapeutics Inc. - From 04/15/24

Stock Information
Company Name: Axsome Therapeutics Inc.
Stock Symbol: AXSM
Market: NASDAQ
Website: axsome.com
Menu
AXSM AXSM Quote AXSM Short AXSM News AXSM Articles AXSM Message Board
Get AXSM Alerts

News, Short Squeeze, Breakout and More Instantly...
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting | Benzinga

AXS-05 in Alzheimer's disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in poole...
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 | Benzinga

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering nove...

Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm | Benzinga

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigat...
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday? | Benzinga

Monday, Axsome Therapeutics Inc (NASDAQ:AXSM) released data from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy pat...

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy | Benzinga

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint) AXS-12 achieved statistically signifi...

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference | Benzinga

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering nove...
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference | Benzinga

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel...

Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones | Benzinga

Axsome Therapeutics Inc (NASDAQ:AXSM) reported fourth-quarter 2023 revenues of $71.53 million, up from $24.37 million a year ago, beating the&...

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst | Benzinga

UBS initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM), a biotech firm focused on developing and marketing therapies for ce...
Previous 10 Next 10